Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05108350
Other study ID # HR20033-101
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date November 9, 2021
Est. completion date December 10, 2021

Study information

Verified date November 2021
Source Shandong Suncadia Medicine Co., Ltd.
Contact Sheng Feng, Ph.D
Phone 13817253036
Email Sheng.feng@hengrui.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial is to assess the bioequivalence between HR20033 FDC tablet and co-administration of SHR3824 tablets and metformin XR tablets. The primary objective is to evaluate bioequivalence of SHR3824 and Metformin in healthy Chinese subjects in the fed state. The secondary objective is to evaluate the safety of HR20033 FDC tablet in healthy Chinese subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date December 10, 2021
Est. primary completion date December 3, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Sign the informed consent before the trial, and fully understand the content, process, and possible adverse reactions of the trial; 2. Must be able to communicate with the investigator, understand and comply with all study requirements; 3. Subject (include their fere) must have not pregnancy plan from 2 weeks prior to dose administration to 6 months after last dose administration and must use effective form of birth control; 4. Male or female subjects aged 18 to 50 (including 18 and 50); 5. Weigh at least 50 kg (for male) and 45 kg (for female), respectively, and have a body mass index (BMI) = 18 and <28 kg/m2. BMI = weight (kg)/[height (m)]2; 6. No clinically significant deviation from normal in medical history, vital signs, physical examination. Exclusion Criteria: 1. Regular smoker within 3 months prior to study drug administration, or quitting smoking less than 30 days until screening; 2. History of allergy to test drugs, allergic constitution (multiple drug and food allergies); 3. A history of alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); those who have abstained from alcohol have not quit for 30 days at the time of screening; 4. Donate blood or lose a lot of blood (>450mL) within three months before screening; 5. Take any drugs that alter liver enzyme activity 28 days before screening; 6. Take any prescription drugs, over-the-counter drugs, any vitamin products or herbal medicines within 14 days before screening; 7. Those who have taken a special diet (including pitaya, mango, grapefruit, etc.) or exercised vigorously within 2 weeks before screening, or other factors that affect drug absorption, distribution, metabolism, and excretion; 8. Combine the following inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as itraconazole, ketoconazole or dronedarone; 9. Significant changes in diet or exercise habits recently; 10. Have taken the research drug or participated in the drug clinical trial within three months before taking the research drug; 11. Have a history of dysphagia or any gastrointestinal disease that affects drug absorption; 12. Suffer from any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers; 13. Subjects who cannot tolerate standard meals (two boiled eggs, a slice of buttered bacon toast, a box of fried potato chips, a cup of whole milk); 14. Abnormal ECG has clinical significance; 15. Female subjects are breastfeeding or have a positive serum pregnancy result during the screening period or the test; 16. Clinical laboratory tests have clinically significant abnormalities, or other clinical findings in the 12 months before screening show clinical significance for the following diseases (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune , Mental or cardiovascular disease); 17. Viral hepatitis (including hepatitis B and C), AIDS antibody, and Treponema pallidum antibody screening are positive (for those with Treponema pallidum antibody positive, additional RPR testing is required); 18. Acute illness or concomitant medication from the screening stage to the study medication; 19. Ingested chocolate, any caffeine-rich or xanthine-rich food or drink 48 hours before taking the study drug; 20. Have taken any alcohol-containing products or a positive alcohol breath test within 48 hours before taking the study medication; 21. Those who have a positive urine drug screen or have a history of drug abuse in the past five years; 22. Have been exposed to metformin and/or SGLT2 inhibitor drugs such as dapagliflozin, empagliflozin, canagliflozin, and empagliflozin within 1 month before administration.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR
SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.
T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR
SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.
T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.
T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shandong Suncadia Medicine Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: Cmax Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Primary Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: AUC0-t Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Primary Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: AUC0-inf (if applicable) Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: Tmax Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: Vz/F Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: CL/F Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary Pharmacokinetics parameters of SHR3824 and Metformin in the fasted and fed state: t1/2 Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary Pharmacokinetics parameters of SHR3824 and Metformin after single and multiple dose: Tmax Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary Pharmacokinetics parameters of SHR3824 and Metformin after single and multiple dose: Ctrough Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary Pharmacokinetics parameters of SHR3824 and Metformin after single and multiple dose: Racc etc Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
Secondary The incidence and severity of adverse events/serious adverse events Based on pre-dose, 0.5-72 hours post-dose sampling times on Day 1 and Day 8
See also
  Status Clinical Trial Phase
Withdrawn NCT04569214 - The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients Phase 2
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT01698528 - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration N/A
Completed NCT00985114 - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity N/A
Active, not recruiting NCT05120219 - A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers Phase 1
Completed NCT04893135 - Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes N/A
Completed NCT02586129 - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes Phase 3
Completed NCT02914743 - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes N/A
Completed NCT04540016 - Mass Balance and Biotransformation of [14C]HSK7653 in Human Phase 1
Completed NCT02429258 - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin Phase 4
Completed NCT01055223 - Fracture Risk With Thiazolidinediones N/A
Terminated NCT02365233 - Fatty Liver Study in Patients With Type II Diabetes Phase 4
Completed NCT05878587 - Burger Allen Exercises in Knee OA With Type II Diabetes N/A
Completed NCT04768673 - A Study to Investigate the PK and Safety of CKD-393 Phase 1
Not yet recruiting NCT05028140 - Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus Phase 3
Terminated NCT01804777 - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes Early Phase 1
Completed NCT01619332 - Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Phase 1/Phase 2
Active, not recruiting NCT06387433 - Effectiveness of an mHealth Mobile App N/A
Not yet recruiting NCT01591525 - Diabetes Mellitus Community Based Screening in Minority Populations N/A
Completed NCT01881074 - Periodontal Treatment Response in Type II Diabetic Patients